After RGSCTT is promogulated, many biotechnological companies actively join hospitals, and apply to US FDA. The first approval is expected to be announced in December, and all companies are staggering in winning the first approval. According to the statistics done by the Taiwan FDA, number of cancer patients is about 80,000 to 90,000 per year. The stage IV patients are about 20, 000 per year. The business opportunity is expected. Ever Supreme Bio Technology recently completed MOU with China Medical University Hospital and other 10 hospitals, and Ever Supreme is also qualified for GTP, with capability for production and technologies. Winning chances for Ever Supreme is turning positive.
(1).jpg)